AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 32 min read$KMTS

Ford Alfred J Jr sold $643K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 27,632 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.25 ($22.61–$23.90, $0.64M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 3, 2026, 11:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest disclosed fact is the CCO’s open-market sale details (shares, price range, total value, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but there is no accompanying guidance, trial, deal, or regulatory development in the text.

03

What to watch

The trades span multiple days and explicitly state no pre-arranged 10b5-1 plan, which can increase scrutiny, but the article provides no context on motivations or future intent.

Relevance 5/10Novelty 5/10Timing: Filed 2026-08-03, covering sales from 2026-07-30 to 2026-08-03.

Background

The article is an SEC Form 4 insider transaction filing for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CCO Alfred J. Ford Jr sold 27,632 KMTS shares in open-market trades for about $642.5K, with no 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or unusual volume emerges.

Evidence & confidence

The filing is a primary-source Form 4 and quantifies the sale size and timing, but it does not include new operational, financial, or regulatory information.

Market effects

Sector

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Regional

Minimal, no macro or cross-regional catalyst is described.

Global

Minimal, no international transaction or global regulatory action is mentioned.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification or tax planning, so the signal may be weaker than the headline implies.

Key entities

  • issuer
    KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Alfred J. Ford Jr

    Chief Commercial Officer who sold 27,632 shares in open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

OCT 20
$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

investing.com2 min
SEP 16
$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.

tipranks.com3 min
SEP 15
$KMTSMed

Kestra (KMTS) Q1 2027 Earnings Call Transcript

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue of $31.0M, up 60% YoY, and raised full-year guidance to $141M. Gross margin increased to 56.5%, driven by volume leverage and cost improvements. The company invested heavily in R&D and commercial expansion, resulting in a GAAP net loss of $44.1M. Management highlighted market share gains and expanded payer coverage for non-ischemic patients.

aol.com2 min
SEP 15
$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

yahoo.com3 min